Key result
Real-world inclisiran is linked to a ~41% reduction in LDLc at 6 months.
Why the study?
Does inclisiran reduce LDL cholesterol levels in a real-world population of patients with or at high risk of ASCVD or FH?
Observational (n=50)
No
Does inclisiran reduce LDL cholesterol levels in a real-world population of patients with or at high risk of ASCVD or FH?
Answers are grounded in this paper and cite their sources.
In a real-world setting, inclisiran effectively reduced LDL cholesterol levels by 44% at 6 months in high-risk patients without significant adverse effects.
Background: A mean relative 50 % reduction of LDL cholesterol (LDLc) levels was observed in randomized studies in patients treated with inclisiran, a small-interfering-RNA therapeutic agent that reduces hepatic synthesis of PCSK9. Less is known on real world and every-day practice patients. Methods: Fifty consecutive patients with or at risk of atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) and treated with inclisiran according to Italian indications were enrolled in an observational study. LDLc levels were followed up. Results: 26 patients had an acute coronary syndrome (ACS), 11 FH; 46 % were on high-intensity statin therapy, 68 % on combination therapy statin/ezetimibe.Mean LDLc level of the study population was 118 ± 12 mg/dl at baseline, 80 ± 18 mg/dl after 3 months, and 70 ± 15 mg/dl after 6 months (ANOVA p < 0.001). The use of inclisiran was associated with significantly reduced LDLc levels of 21 % at 1 month and 44 % at 6 months.LDLc reduction in patients with ACS was statistically significant and comparable with chronic CS. Patients receiving a background combination therapy (statin/ezetimibe) showed a greater reduction in circulating LDLc levels than patients using inclisiran alone. No significant side effects or treatment drop out were observed during follow up. Rates of subjects with LDLc levels below 70 mg/dl (Italian Drug Agency target) increased from 0 % at baseline to 56 % at 6 months (p < 0.001). Conclusions: In a real-world population 3-6 months of therapy with inclisiran provide consistent and effective reduction in LDLc levels without significant adverse side-effects.
No takes yet. Share an insight, caveat, or question.
Centola et al. (2025) conducted an observational in Atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) (n=50). Inclisiran vs. Baseline was evaluated on Mean LDLc level (p=<0.001). In a real-world registry, inclisiran treatment reduced mean LDLc levels from /dl at baseline to /dl at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: